Ardagh Group S.A. ARD
24.75 +24.75
Day range unavailable
52-week range unavailable
- Earnings date
- Oct 28, 2021
No chart data for this range yet.
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Price target (mean) —
Ratings (0m) 10 7 buy · 3 hold · 0 sell
- Strong buy2
- Buy5
- Hold3
- Sell0
- Strong sell0
Next earnings
Oct 28, 2021
Expected Oct 28, 2021. Consensus EPS estimate 0.00.
Financials — quick view
ARD Revenue — annual 6.73B
ARD Net income — annual 35.00M
ARD EPS — annual 0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 28, 2021 | Sep 1, 2021 | 0.49 | — | — | — |
| Aug 3, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Apr 29, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Feb 16, 2021 | Dec 1, 2020 | 0.26 | — | — | — |
| Oct 22, 2020 | Sep 1, 2020 | 0.44 | — | — | — |
| Jul 23, 2020 | Jun 1, 2020 | 0.35 | — | — | — |
News
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data 
Ardagh Metal Packaging S.A. - Third Quarter 2026 Results 
Ardagh Metal Packaging S.A. Declares Quarterly Dividend 
Ardagh Group Announces Sale of Trivium Packaging 
Ardagh Metal Packaging: A Beverage Can Manufacturer That Needs To Improve Its Balance Sheet 
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD 
AARD UPCOMING DEADLINE: SueWallSt Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm 
AARD DEADLINE: SueWallSt Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline 
AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky 
Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101
Your note
Sign in to keep a note on ARD — it syncs with the Stock Master app.